<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">109425</article-id>
<article-id pub-id-type="doi">10.7554/eLife.109425</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.109425.1</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.1</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Cell Biology</subject>
</subj-group>
</article-categories><title-group>
<article-title>Hepatic Transthyretin knockdown alleviates NAFLD by enhancing SERCA2 function and inhibiting endoplasmic reticulum stress</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>He</surname>
<given-names>Yingzi</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Tian</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Qiu</surname>
<given-names>Ruojun</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Bingyang</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Shuo</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Jianan</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zheng</surname>
<given-names>Fenping</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<email>3407004@zju.edu.cn</email>
</contrib>
<aff id="a1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00ka6rp58</institution-id><institution>Department of Endocrinology, the Affiliated Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University</institution></institution-wrap>, <city>Hangzhou</city>, <country country="CN">China</country></aff>
<aff id="a2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03k14e164</institution-id><institution>Department of Endocrinology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College)</institution></institution-wrap>, <city>Hangzhou</city>, <country country="CN">China</country></aff>
<aff id="a3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00a2xv884</institution-id><institution>Department of Endocrinolgy, The Fourth Affiliated Hospital, College of Medicine, Zhejiang University</institution></institution-wrap>, <city>Yiwu</city>, <country country="CN">China</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Rutkowski</surname>
<given-names>Tom</given-names>
</name>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-6586-4449</contrib-id><role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/036jqmy94</institution-id><institution>University of Iowa</institution>
</institution-wrap>
<city>Iowa City</city>
<country country="US">United States</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Ron</surname>
<given-names>David</given-names>
</name>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3014-5636</contrib-id><role>Senior Editor</role>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/013meh722</institution-id><institution>University of Cambridge</institution>
</institution-wrap>
<city>Cambridge</city>
<country country="GB">United Kingdom</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<fn fn-type="coi-statement"><p>Competing interests: No competing interests declared</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2025-12-04">
<day>04</day>
<month>12</month>
<year>2025</year>
</pub-date>
<volume>14</volume>
<elocation-id>RP109425</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2025-10-15">
<day>15</day>
<month>10</month>
<year>2025</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2025-10-17">
<day>17</day>
<month>10</month>
<year>2025</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2025.10.15.25338095"/>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2025, He et al</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>He et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-109425-v1.pdf"/>
<abstract><p>Endoplasmic reticulum (ER) stress is considered a key trigger in the nonalcoholic fatty liver disease (NAFLD). Dysfunction of sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) leads to insufficient ER Ca<sup>2+</sup> storage, thus activating ER stress. Transthyretin (TTR), expressed and secreted by the liver, may function as a new “hepatokine” related with insulin resistance (IR). However, the role of TTR in NAFLD remains unclear. We firstly found the hepatic <italic>Ttr</italic> mRNA expression was elevated in NAFLD patients. TTR over-expression exacerbated steatosis in fatty livers, while TTR knockdown alleviated IR, steatosis, inflammation, and upregulated SERCA2 expression, leading to reduced ER stress in NAFLD mice. Consistently, TTR knockdown alleviated lipid deposition in steatotic hepatocytes. TTR stimulation of hepatocytes increased cytosolic Ca²⁺ and decreased ER Ca²⁺. Conversely, in steatotic AML12 cells, TTR knockdown increased ER calcium storage and mitigated the cytosolic calcium pulse induced by thapsigargin. Then using immunofluorescence and co-immunoprecipitation, we further confirmed the interaction between TTR and SERCA2. In conclusion, TTR knockdown ameliorated liver steatosis and inflammation in NAFLD, which might be related to the improvement of cellular calcium homeostasis and ER stress by reversing SERCA2 function.</p>
</abstract>
<funding-group>
<award-group id="par-1">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id>
<institution>National Natural Science Foundation of China</institution>
</institution-wrap>
</funding-source>
<award-id>81870583</award-id>
<principal-award-recipient>
<name>
<surname>Zheng</surname>
<given-names>Fenping</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-2">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004731</institution-id>
<institution>Natural Science Foundation of Zhejiang Province</institution>
</institution-wrap>
</funding-source>
<award-id>ZCLQN25H0701</award-id>
<principal-award-recipient>
<name>
<surname>He</surname>
<given-names>Yingzi</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>The contents of the published material are solely the responsibility of the individual authors and do not reflect the view of any of the funding bodies.</funding-statement>
</funding-group>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Nonalcoholic fatty liver disease (NAFLD) is a continuous spectrum that includes simple non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), with a portion progressing to cirrhosis and even hepatocellular carcinoma. NAFLD is a chronic metabolic disease closely related to obesity and metabolic syndrome(<xref ref-type="bibr" rid="c1">Quek et al., 2023</xref>). With an “obesity epidemic” raging throughout many parts of the world, NAFLD has become the most common chronic liver disease worldwide(<xref ref-type="bibr" rid="c2">Henry et al., 2022</xref>; <xref ref-type="bibr" rid="c3">Paik et al., 2020</xref>). However, the pathogenesis of this disease is complex and largely unknown. The “multiple hits theory” indicates that factors such as insulin resistance (IR), mitochondrial dysfunction, endoplasmic reticulum (ER) stress, changes in gut microbiota, genetics, and epigenetics are all involved(<xref ref-type="bibr" rid="c4">Buzzetti et al., 2016</xref>; <xref ref-type="bibr" rid="c5">Loomba et al., 2021</xref>). The complex pathogenesis poses a significant challenge for discovering effective treatments for the disease.</p>
<p>Excessive and sustained ER stress is considered to be a key trigger in the progression of NAFLD(<xref ref-type="bibr" rid="c6">Rutkowski et al., 2008</xref>). ER is the primary sub-cellular organelle for lipid synthesis and calcium store. The storage of calcium by ER is the most critical process for maintaining the intra-cellular calcium homeostasis. In recent years, the impact of calcium signaling on NAFLD, particularly in terms of lipid accumulation, has garnered significant attention, and targeting the regulation of calcium homeostasis emerges as a novel intervention strategy for combating NAFLD(<xref ref-type="bibr" rid="c7">Park and Lee, 2014</xref>). The sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) is the sole calcium uptake channel and is essential for maintaining the high concentration of Ca<sup>2+</sup> in the ER(<xref ref-type="bibr" rid="c8">Periasamy and Kalyanasundaram, 2007</xref>; <xref ref-type="bibr" rid="c9">Vangheluwe et al., 2005</xref>). Dysfunction of SERCA leads to insufficient Ca<sup>2+</sup> storage in the ER, resulting in protein misfolding and subsequently activating ER stress and thus altering lipid synthesis(<xref ref-type="bibr" rid="c10">Krebs et al., 2015</xref>). SERCA2 is the primary isoform of SERCA in the liver(<xref ref-type="bibr" rid="c9">Vangheluwe et al., 2005</xref>). Plenty of studies have demonstrated that enhancing the function of SERCA2 can ameliorate ER stress and delay the progression of NAFLD(<xref ref-type="bibr" rid="c11">Jung et al., 2018</xref>; <xref ref-type="bibr" rid="c7">Gao et al., 2018</xref>; <xref ref-type="bibr" rid="c13">Park et al., 2010</xref>; <xref ref-type="bibr" rid="c14">Kang et al., 2016</xref>). Therefore, targeting the modulation of SERCA function to improve ER calcium homeostasis may offer a novel strategy for the treatment of NAFLD.</p>
<p>Vast researches indicate that liver is capable of expressing a variety of genes that encode extracellular proteins, termed “hepatokines”, which participate in the metabolic regulation by establishing inter-organizational “cross-talk” through autocrine, paracrine, and endocrine actions(<xref ref-type="bibr" rid="c15">Weigert et al., 2019</xref>; <xref ref-type="bibr" rid="c16">Iroz et al., 2015</xref>). Our studies have shown that transthyretin (TTR) may function as a “hepatokine”. In different mouse models of IR, hepatic TTR expression and secretion are increased. Excessive TTR induces the occurrence of IR and inhibit the insulin-sensitizing effect of exercise in obese mice(<xref ref-type="bibr" rid="c17">He et al., 2021</xref>). Another study also showed that TTR is directly involved in the regulation of IR and glucose metabolism(<xref ref-type="bibr" rid="c18">Zemany et al., 2015</xref>). Additionally, its impact on calcium homeostasis is also noteworthy. TTR causes Ca<sup>2+</sup> oscillations in pancreatic cells(<xref ref-type="bibr" rid="c19">Dekki et al., 2012</xref>) and in skeletal muscle cells, as our previous findings reported(<xref ref-type="bibr" rid="c20">Wu et al., 2023</xref>). However, the association between TTR and the development of NAFLD is still unclear. Given the pivotal role of IR and calcium homeostasis in the development of NAFLD, we hypothesize that TTR may be involved in the onset and progression of NAFLD.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Expression of TTR is increased in patients with NASH and TTR over-expression causes hepatic lipid deposition in vitro and in vivo</title>
<p>In our previous study, we found increased hepatic <italic>Ttr</italic> expression and secretion in patients with metabolic syndrome and in different obese mouse models(<xref ref-type="bibr" rid="c17">He et al., 2021</xref>). NAFLD is also considered a state of IR, and a complication of obesity and metabolic syndrome, so we measured <italic>Ttr</italic> mRNA expression in the liver biopsy specimen of patients with NASH. <xref rid="fig1" ref-type="fig">Figure 1A</xref> demonstrated that the patients with NASH exhibited higher hepatic <italic>Ttr</italic> mRNA expression compared with the non-NAFLD individuals. Then we constructed mouse models with TTR over-expression by tail vein injection of TTR-expressing adenovirus (Ad-<italic>Ttr</italic>) into the mice after 8 weeks of high-fat-diet (HFD) feeding. The hepatic TTR expression in mice fed on HFD or normal diet (ND) was increased after injection with Ad-<italic>Ttr</italic> (<xref rid="fig1" ref-type="fig">Figure 1B</xref>), as was the increased serum TTR levels (<xref rid="fig1" ref-type="fig">Figure 1C</xref>). TTR over-expression didn’t affect liver lipid contents in ND mice, but further aggravated hepatic steatosis in HFD mice (<xref rid="fig1" ref-type="fig">Figure 1D</xref>, <xref ref-type="fig" rid="fig1">E</xref>). In <italic>vitro</italic>, both 0.75 mM of free fatty acids (FFAs) and 400 µM of palmitic acid (PAs) elevated <italic>Ttr</italic> mRNA expression in AML12 cells (<xref ref-type="supplementary-material" rid="supp1">Supplementary Figure 1</xref>). We consistently found that TTR up-regulation, achieved by <italic>Ttr</italic>-adenovirus infection exacerbated FFAs-induced lipid deposition in AML12 cells (<xref rid="fig1" ref-type="fig">Figure 1F-H</xref>). Thus, we firstly confirmed that excessive TTR expression under IR state in the liver leads to lipid deposition within it.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1.</label>
<caption><title>Elevated TTR is associated with the development of NAFLD.</title>
<p>(A) Quantitative real-time PCR (qRT-PCR) detected <italic>Ttr</italic> mRNA levels from liver sections in NASH patients and non-NAFLD controls (n = 5 per group). (B-E) TTR was overexpressed in ND or HFD-fed mice by tail vein injection of adenovirus (n = 4 per group). (B) Western blot analysis of hepatic protein level of TTR. (C) Serum TTR levels were detected by ELISA. Hepatic TG contents (D) and Oil Red O staining (E) in mouse liver tissues. Scale bar: 100 μm. (F-H) TTR was overexpressed in AML12 cells by adenovirus. (F) Western blot analysis of protein level of TTR-FLAG. Hepatic TG contents (G) and Oil Red O staining (H) in AML12 cells. Scale bar: 100 μm. Data are shown as the mean ± SEM. <italic>P</italic> values were from 2-tail unpaired <italic>t</italic> test (A) and 1-way ANOVA (B, C, D and G). <sup>#</sup><italic>P</italic> = 0.057, *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001. ND, normal diet; HFD, high fat diet; Ad-<italic>Ttr</italic>, Adenovirus-<italic>Ttr</italic>; NS, no significance; TTR-OE, TTR overexpression; TG, triglyceride.</p></caption>
<graphic xlink:href="25338095v1_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2b">
<title>Liver-specific TTR knockdown (TTR-KD) improved glucose tolerance and insulin tolerance in HFD and Gubra-Amylin NASH (GAN)-diet mice</title>
<p>To further investigate whether TTR plays a role in the development of NAFLD, we established HFD/GAN diet-induced mouse models with liver-specific TTR knockdown by tail vein injection of adeno-associated virus-sh<italic>Ttr</italic> bearing TBG promoter (AAV-TBG-sh<italic>Ttr</italic>). After 8 weeks of AAV injection into HFD or GAN-diet mice, the hepatic expression and secretion of TTR into circulation decreased compared with the control groups (<xref rid="fig2" ref-type="fig">Figure 2A</xref>, <xref ref-type="fig" rid="fig2">B</xref>, <xref ref-type="fig" rid="fig2">C</xref>, <xref ref-type="fig" rid="fig2">G</xref>, <xref ref-type="fig" rid="fig2">H</xref>, <xref ref-type="fig" rid="fig2">I</xref>). Specific TTR knockdown in liver didn’t decrease the body weight of mice fed on 19 weeks of HFD or 17 weeks of GAN diet (<xref rid="fig2" ref-type="fig">Figure 2D</xref>, <xref ref-type="fig" rid="fig2">J</xref>) and the food intake of mice fed with GAN diets (<xref ref-type="supplementary-material" rid="supp1">Supplementary Figure 2</xref>), which was comparable to mice fed on ND. However, glucose tolerance and insulin sensitivity were significantly improved in mice fed on HFD or GAN diet by TTR knockdown (<xref rid="fig2" ref-type="fig">Figures 2E</xref>, <xref ref-type="fig" rid="fig2">K</xref>, <xref ref-type="fig" rid="fig2">F</xref>, <xref ref-type="fig" rid="fig2">L</xref>).</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2.</label>
<caption><title>The effect of TTR-KD on insulin resistance.</title>
<p>(A-F) TTR knockdown was achieved in the HFD-fed mice as mentioned in the Materials and Methods section (n = 7-8 per group). (A) qRT-PCR detected hepatic <italic>Ttr</italic> mRNA levels in HFD-fed mice. Serum TTR levels were examined by western blot (B) and ELISA (C). (D) The body weight of HFD-fed mice was recorded per week for 19 weeks. Blood glucose levels and AUC of IPGTT (E) and ITT (F) in HFD-fed mice. (G-L) TTR knockdown was achieved in the GAN diet-fed mice as described in the Materials and Methods section (n = 5–6 per group). (G) qRT-PCR detected hepatic <italic>Ttr</italic> mRNA levels in GAN diet-fed mice. Serum TTR levels were measured by western blot (H) and ELISA (I). (J) The body weight of GAN diet-fed mice was recorded per week for 17 weeks. Blood glucose levels and AUC of OGTT (K) and ITT (L) in GAN diet-fed mice. Data are shown as the mean ± SEM. <italic>P</italic> values were from 1-way ANOVA (A, C, D, J, E, F, G, I, K and L). <sup>#</sup><italic>P</italic> = 0.07, *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001. TTR-KD, TTR knockdown; GAN, Gubra-Amylin NASH; IPGTT, intraperitoneal glucose tolerance test; ITT, insulin tolerance test; OGTT, oral glucose tolerance test; AUC, area under curve.</p></caption>
<graphic xlink:href="25338095v1_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2c">
<title>Liver-specific TTR knockdown improved hepatic steatosis, inflammation, serum lipid and transaminase levels in HFD and GAN-diet mice</title>
<p>An increase in liver weight is an early symptom of fatty liver. We found that the liver weight (corrected by body weight) was significantly decreased in HFD mice by TTR knockdown (<xref rid="fig3" ref-type="fig">Figure 3A</xref>). Regarding to GAN-diet mice, the representative liver of TTR-KD mice was less greasy and redder than that of the control mice, although there was no difference in their liver weight (<xref rid="fig4" ref-type="fig">Figure 4</xref> <xref ref-type="fig" rid="fig4">A</xref>, <xref ref-type="fig" rid="fig4">B</xref>). We further found that the liver TG contents, as well as lipid droplets in both HFD and GAN-diet mice, were decreased by TTR knockdown (<xref rid="fig3" ref-type="fig">Figure 3B</xref>, <xref ref-type="fig" rid="fig3">C</xref>) (<xref rid="fig4" ref-type="fig">Figure 4C</xref>, <xref ref-type="fig" rid="fig4">D</xref>).</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3.</label>
<caption><title>TTR knockdown improved liver lipid deposition, liver function as well as inflammatory gene expression in HFD-fed mice.</title>
<p>Liver/body weight ratio (A) and hepatic TG contents (B) were measured in the TTR-KD and control mice. (C) Representative images of Oil Red O and H&amp;E staining of liver tissue; scale bar: 100 μm. (D) Liver steatosis, lobular inflammation and NAFLD activity scores in HFD-fed mice. Liver function evaluated by serum ALT, AST levels (E) and lipid levels (F). (G) Related gene expressions of liver inflammation and fibrosis. (H) Representative images of Masson’s trichome and Sirius red staining of liver sections; scale bar: 100 μm. n = 7-8 per group. Data are shown as the mean ± SEM. <italic>P</italic> values were from 2-tail unpaired <italic>t</italic> test (D) and 1-way ANOVA (A, B, E, F and G). <sup>#</sup><italic>P</italic> = 0.06, *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001. H&amp;E, hematoxylin and eosin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.</p></caption>
<graphic xlink:href="25338095v1_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4.</label>
<caption><title>TTR knockdown improved liver lipid deposition, liver function as well as inflammatory gene expression, but did not significantly alter liver tissue fibrosis in GAN diet-fed mice.</title>
<p>Representative images of general liver appearance (A), liver/body weight ratio (B) and hepatic TG contents (C) in the TTR-KD and control mice, respectively. (D) Representative images of Oil Red O and H&amp;E staining of liver tissue; scale bar: 100 μm. (E) Liver steatosis, lobular inflammation and NAFLD activity scores in GAN diet-fed mice. Liver function evaluated by serum ALT, AST levels (F) and lipid levels (G). (H) Related gene expressions of liver inflammation and fibrosis. (I) Representative images of Masson and Sirius Red staining of liver sections; scale bar: 100 μm. n = 5-6 per group. Data are shown as the mean ± SEM. <italic>P</italic> values were from 2-tail unpaired <italic>t</italic> test (E) and 1-way ANOVA (B, C, F, G and H). <sup>#</sup><italic>P</italic> = 0.06, *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001.</p></caption>
<graphic xlink:href="25338095v1_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>The NAFLD activity score (NAS) is widely used for evaluating the severity of NAFLD, including steatosis, lobular inflammation and ballooning degeneration(<xref ref-type="bibr" rid="c21">Kleiner et al., 2005</xref>). We observed no obvious hepatocyte ballooning in the livers of mice fed on HFD or GAN diet, with an average NAS of 5.17 (<xref rid="fig3" ref-type="fig">Figure 3D</xref>) or 5.05 (<xref rid="fig4" ref-type="fig">Figure 4E</xref>), respectively. Yet, TTR knockdown significantly decreased the NAS (<xref rid="fig3" ref-type="fig">Figure 3D</xref>, <xref ref-type="fig" rid="fig4">4E</xref>), alanine aminotransferase levels (<xref rid="fig3" ref-type="fig">Figure 3E</xref>, <xref ref-type="fig" rid="fig4">4F</xref>), lipid levels (<xref rid="fig3" ref-type="fig">Figure 3F</xref>, <xref ref-type="fig" rid="fig4">4G</xref>), and the gene expressions of inflammatory factors of <italic>TNF-α</italic> and <italic>IL-1β</italic> (<xref rid="fig3" ref-type="fig">Figure 3G</xref>, <xref ref-type="fig" rid="fig4">4H</xref>), indicating the improvement of hepatic steatosis and inflammation in both mice. Early collagen deposition localizes to zone 3 of the hepatic lobule, showing perisinusoidal fibrosis with delicate blue fibers on Masson stain(<xref ref-type="bibr" rid="c22">Gallage et al., 2022</xref>). While TTR knockdown reduced the expression of fibrotic genes (<italic>Col1a1</italic>, <italic>Col1a2</italic>, and <italic>TGF-β 1</italic>) and decreased collagen deposition (assessed by Masson’s trichrome and Sirius red staining) in GAN-diet-fed mice (<xref rid="fig4" ref-type="fig">Figure 4H</xref>, <xref ref-type="fig" rid="fig4">I</xref>), but not in HFD-fed mice (<xref rid="fig3" ref-type="fig">Figure 3G</xref>, <xref ref-type="fig" rid="fig4">H</xref>).</p>
<p>Consistently, effectively knockdown of TTR expression in FFAs-induced AML12 cells by <italic>Ttr</italic> siRNA transfection (<xref ref-type="supplementary-material" rid="supp1">Supplementary Figure 3A, B</xref>) decreased the positive area in Nile red, as well as intra-cellular TG levels (<xref ref-type="supplementary-material" rid="supp1">Supplementary Figure 3C, D</xref>).</p>
</sec>
<sec id="s2d">
<title>TTR overexpression or knockdown did not influence mouse thyroid function</title>
<p>TTR plays a critical role as a primary thyroid hormone transporter in rodents. We thus evaluated the impact of TTR knockdown on circulating thyroid hormone levels. We found that circulating serum free thyroxine (FT4) levels were not affected by TTR knockdown (<xref ref-type="supplementary-material" rid="supp1">Supplementary Figure 4</xref>), indicating that TTR’s effect on IR or NAFLD was unlikely related to thyroid hormones.</p>
</sec>
<sec id="s2e">
<title>Liver-specific TTR knockdown affects lipid synthesis at ER levels in mice with NAFLD</title>
<p>TTR knockdown consistently ameliorated hepatic lipid accumulation across different NAFLD mouse models and in steatotic hepatocytes. To further explore the molecular mechanisms of improved NAFLD by TTR knockdown, we conducted transcriptomic analysis and non-targeted lipidomics analysis of liver samples from HFD mice. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed that the differentially expressed genes (DEGs) were primarily enriched in glycerolipid metabolism and lipid and atherosclerosis (<xref rid="fig5" ref-type="fig">Figure 5A</xref>). Gene Ontology (GO) analysis showed the DEGs in biological processes and cell components were involved in ER lipid metabolic process and ER lipid transport and binding (<xref rid="fig5" ref-type="fig">Figure 5A</xref>). Then we performed a heat map of DEGs associated with ER lipid metabolism, indicating the down-regulation of ER lipid synthesis-related genes, such as <italic>SCD-1</italic>, <italic>ELOVL5</italic>, <italic>GPAT3</italic>, <italic>MOGAT1</italic>, in the livers of HFD mice with TTR knockdown (<xref rid="fig5" ref-type="fig">Figure 5B</xref>). In addition, non-targeted lipidomics analysis revealed that the main different lipid species were TG and diacylglycerol (DAG) (<xref rid="fig5" ref-type="fig">Figure 5C</xref>). As the smooth ER is the primary site for hepatic DAG and TG production, our findings suggested that TTR knockdown was most likely to affect the glycerolipid synthesis at the ER level.</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Figure 5.</label>
<caption><title>TTR knockdown downregulated the expression of ER lipid synthesis-related genes.</title>
<p>(A-C) Bioinformatics analyses for the relationship between TTR knockdown and ER lipid metabolism in the liver of NAFLD mice (n = 3 per group). (A) KEGG pathway enrichment analysis and GO analysis for biological processes, cell components and molecular function regulated by differentially expressed genes (DEGs) (<italic>P</italic>&lt; 0.05, ≥ 1.0-fold change). (B) Representative heat map of DEGs associated with ER lipid metabolism. (C) Non-targeted lipidomics analysis showed a lipid bar plot in differences of lipid species between TTR-KD mice and control mice fed on HFD. (D-I) qRT-PCR was used to confirm DEGs that were enriched in ER lipid metabolism-related pathways (n = 7-8 per group in HFD mice; n = 5-6 per group in GAN-diet mice). The mRNA expression levels of genes related to de novo lipogenesis (D, G), fatty acid oxidation (E, H) and ER lipid synthesis (F, I) in the livers of TTR-KD mice fed on HFD and GAN diet. Data are shown as the mean ± SEM. <italic>P</italic> values were from 1-way ANOVA. <sup>#</sup><italic>P</italic> = 0.07, *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001. KEGG, the Kyoto Encyclopedia of Genes and Genomes; GO, Gene Ontology.</p></caption>
<graphic xlink:href="25338095v1_fig5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Indeed, we confirmed that liver-specific TTR knockdown significantly down-regulated the expression of ER lipid synthesis-related genes (mainly <italic>SCD-1</italic>, <italic>ELOVL5</italic>, <italic>GPAT3</italic>, <italic>GPAT4</italic> and <italic>DGAT1</italic>) in the livers of HFD- or GAN diet-fed mice (<xref rid="fig5" ref-type="fig">Figure 5F</xref>, <xref ref-type="fig" rid="fig5">I</xref>). However, it didn’t alter the expression of genes related to de novo lipogenesis (DNL) or fatty acid oxidation (<xref rid="fig5" ref-type="fig">Figure 5D</xref>, <xref ref-type="fig" rid="fig5">E</xref>, <xref ref-type="fig" rid="fig5">G</xref> and <xref ref-type="fig" rid="fig5">H</xref>), indicating that TTR modulates lipid metabolism at the ER level.</p>
</sec>
<sec id="s2f">
<title>Liver-specific TTR knockdown inhibited hepatic ER stress in NAFLD mice, and upregulated SERCA2 expression both in vivo and in vitro</title>
<p>Prolonged and excessive ER stress plays a significant role in the development of NAFLD, through the exacerbation of hepatic steatosis, hepatocyte apoptosis, and inflammation(<xref ref-type="bibr" rid="c23">Flessa et al., 2022</xref>; <xref ref-type="bibr" rid="c24">Lebeaupin et al., 2018</xref>). We then assessed three ER stress pathway of PERK, IRE1α, and ATF6 in the livers of NAFLD mice fed on HFD and GAN diet. Compared with the control ND mice, HFD and GAN diet induced hepatic ER stress, as indicated by the increased protein levels of p-eIF2α, ATF6 and p-IRE1α (<xref rid="fig6" ref-type="fig">Figure 6A</xref>, <xref ref-type="fig" rid="fig6">B</xref>), all of which were reversed by TTR knockdown except for p-IRE1α (<xref rid="fig6" ref-type="fig">Figure 6A</xref>, <xref ref-type="fig" rid="fig6">B</xref>). We further observed the expressions of ER stress chaperone proteins, particularly GRP78, but did not detect any significant differences in the livers of HFD or GAN diet mice (<xref ref-type="supplementary-material" rid="supp1">Supplementary Figure 5</xref>).</p>
<fig id="fig6" position="float" orientation="portrait" fig-type="figure">
<label>Figure 6.</label>
<caption><title>TTR knockdown inhibited ER stress and upregulated SERCA2 expression in the liver of NAFLD mice.</title>
<p>Western blot analysis of the protein levels of p-PERK/p-eIF2α/CHOP and ATF6 signaling pathways in the liver of HFD mice (A) and GAN-diet mice (B). SERCA2 protein expression examined by western blot in the liver of HFD mice (C), GAN-diet mice (D), and FFA-induced AML12 cells transfected with siRNA (E). n = 7-8 per group in HFD mice; n = 5-6 per group in GAN-diet mice. Data are shown as the mean ± SEM. <italic>P</italic> values were from 1-way ANOVA. <sup>#</sup><italic>P</italic> = 0.06, *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001.</p></caption>
<graphic xlink:href="25338095v1_fig6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>ER Ca<sup>2+</sup> at high concentrations, primarily maintained by the SERCA, was essential for the ER function; and SERCA dysfunction can deplete ER Ca<sup>2+</sup> content, impairing the activity of Ca<sup>2+</sup>-dependent folding enzymes and chaperones, thereby leading to ER stress(<xref ref-type="bibr" rid="c10">Krebs et al., 2015</xref>). SERCA2 is the predominant sub-type of SERCA in the liver. In our NAFLD mice fed on HFD or GAN diet, hepatic SERCA2 protein levels were significantly reduced compared to the control mice fed on ND, while TTR knockdown reversed inhibited SERCA2 levels (<xref rid="fig6" ref-type="fig">Figure 6C</xref>, D). Consistently, the upregulation of SERCA2 protein levels was found in steatotic AML12 cells transfected with <italic>Ttr</italic> siRNA (<xref rid="fig6" ref-type="fig">Figure 6E</xref>). These results suggest that TTR knockdown may increase SERCA2 levels and alleviate ER stress in the liver of NAFLD.</p>
</sec>
<sec id="s2g">
<title>TTR could be “taken up” by hepatocytes and localized close to the ER</title>
<p>TTR, synthesized in liver cells, is released into the circulation to function as a hormone transporter protein. Exogenous TTR enters various cells via internalization, including islet cells and skeletal muscle cell(<xref ref-type="bibr" rid="c17">He et al., 2021</xref>; <xref ref-type="bibr" rid="c19">Dekki et al., 2012</xref>). However, it remains unclear whether the same applies to the hepatocyte. We found that exogenous Alexa Fluor 488-labeled TTR probes emitted fluorescence signals within the cytoplasm of AML12 cells by continuous con-focal live-cell imaging. These signals overlapped with those of mCherry-ER-3, a fusion of mCherry fluorescent protein with the KDEL sequence, which serves as an ER marker (<xref rid="fig7" ref-type="fig">Figure 7A</xref>). In addition, we confirmed the co-localization of TTR and Calnexin, a marker protein for ER membrane by immunofluorescence staining in both AML12 and HepG2 cells (<xref rid="fig7" ref-type="fig">Figure 7B</xref>). All these results support the idea that secreted TTR could be taken up by hepatocytes and spatially localized near the ER.</p>
<fig id="fig7" position="float" orientation="portrait" fig-type="figure">
<label>Figure 7.</label>
<caption><title>TTR could be “taken up” by hepatocytes and localized close to the ER.</title>
<p>(A) AML12 cells transfected with the mCherry-ER-3 plasmid for 48 hours were then subjected to serum starvation for 6 hours, followed by the addition of 50 μg/mL Alexa Fluor 488 labeling TTR probes and incubated at 37°C in the dark for 30 minutes. After washing off the free probes, live cell imaging was immediately performed by confocal microscope. Alexa Fluor 488 labeling TTR was observed at an excitation wavelength of 488 nm, while the ER fluorescing red was visible at an excitation wavelength of 594 nm; scale bars: 10 μm (up), 5 μm (down). (B) Immunofluorescence staining of TTR and Calnexin in AML12 and HepG2 cells using confocal microscopy. TTR was observed at an excitation wavelength of 594 nm, and Calnexin at 488 nm. Nuclei were stained with DAPI. Scale bar: 5 μm.</p></caption>
<graphic xlink:href="25338095v1_fig7.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2h">
<title>TTR silencing improved calcium homeostasis between the cytoplasm and the ER</title>
<p>As we have found that TTR’s knockdown in liver activated SERCA2 and inhibited ER stress, as well as the exogenous TTR uptake being closely localized to the ER, we further investigated the impact of TTR on the regulation of calcium homeostasis in hepatocytes. We found the cytosolic Ca<sup>2+</sup> levels, using Fluo-8 AM incubation, were significantly increased after exogenous TTR treatment (10 μg/ml) over time (<xref rid="fig8" ref-type="fig">Figure 8A</xref>). While the ER Ca<sup>2+</sup> levels, indicated by pcDNA-D1ER plasmid transfection, was markedly decreased (<xref rid="fig8" ref-type="fig">Figure 8B</xref>), suggesting potential impairment of SERCA2 function. Indeed, TTR overexpression combined with 5 μM thapsigargin (Tg, a SERCA inhibitor) pretreatment synergistically increased the fluorescence intensity of cytosolic Ca<sup>2+</sup> compared to controls (<xref rid="fig8" ref-type="fig">Figure 8C</xref>); while TTR-KD stable cell lines showed a gentler increase in fluorescence intensity (<xref rid="fig8" ref-type="fig">Figure 8D</xref>). These findings suggest a possible role of TTR in the calcium homeostasis of hepatocytes by regulating SERCA2 activity.</p>
<fig id="fig8" position="float" orientation="portrait" fig-type="figure">
<label>Figure 8.</label>
<caption><title>The effect of TTR on calcium homeostasis in AML12 cells.</title>
<p>After the treatment of TTR (10 μg/ml) or PBS, the fluorescence intensity of Ca<sup>2+</sup>change was monitored in Fluo-8 AM-loaded AML12 cells (A) and in AML12 cells with pcDNA-D1ER plasmid transfection (B). 5 μM Tg was added to block calcium transport from the cytosol to the ER. The fluorescence intensity of Ca<sup>2+</sup> change was detected in TTR-OE AML12 cells by adenovirus (C) and in TTR-KD stable cell lines (D). AML12 cells were incubated with BSA or FFA for 12 h. (E) Resting cytosolic calcium signals were detected in the TTR-KD stable cell lines by Cal-590 AM loading; scale bar: 10 μm. (F) Statistical chart of resting cytosolic calcium intensity in stable cell lines induced by FFA or BSA. (G) After the treatment of Tg (5 μM), the fluctuation of cytosolic calcium signal was monitored in Cal-590 AM-loaded AML12 cells or TTR-KD stable cell lines induced by FFA or BSA. (H) Statistical chart of the peak release ratio of cytosolic calcium intensity caused by Tg stimulation in stable cell lines induced by FFA or BSA. (I) Relative SERCA2 activity in BSA/FFA treated AML12 cells with <italic>Ttr</italic> siRNA infection or not. The activity of SERCA was calculated from the hydrolyzed ATP level (nmol) normalized with the protein content (mg) and reaction time (min). Data are shown as the mean ± SEM. <italic>P</italic> values were from 2-tail unpaired <italic>t</italic> test (A, B, C and D) and 1-way ANOVA (F, H). n = 10-20 cells per group. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001. Tg, thapsigargin.</p></caption>
<graphic xlink:href="25338095v1_fig8.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Abnormal calcium homeostasis contributes to NAFLD, we thus further assessed the calcium homeostasis as well as TTR’s effect on it in steatotic hepatocytes. FFA treatment significantly increased the basal cytosolic Ca<sup>2+</sup> compared to the bovine serum albumin (BSA) treatment; while this increase was partially attenuated upon TTR knockdown (<xref rid="fig8" ref-type="fig">Figure 8E</xref>, <xref ref-type="fig" rid="fig8">F</xref>). Upon Tg stimulation, FFA-induced cytosolic Ca<sup>2+</sup> fluctuation was exacerbated, and this effect was also flattened by TTR knockdown (<xref rid="fig8" ref-type="fig">Figure 8G</xref>, <xref ref-type="fig" rid="fig8">H</xref>). Compared to BSA-treated controls, FFA-treated AML12 cells exhibited significantly reduced SERCA2 activity, as measured by ATPase activity; while TTR knockdown reversed the SERCA2 activity inhibited by FFA (<xref rid="fig8" ref-type="fig">Figure 8I</xref>). Thus, in both steatotic and non-steatotic hepatocytes, TTR fulfilled a function similar to that of Tg, targeting SERCA2 activity.</p>
</sec>
<sec id="s2i">
<title>TTR co-localized with SERCA2 and interacted with SERCA2 in HEK293T cells and hepatocytes</title>
<p>Our prior findings suggested that the uptake of TTR led to its location in the ER area and might exert an inhibitory effect on SERCA2 activity; we then explored the interaction between TTR and SERCA2. We validated the co-localization of TTR and SERCA2, showing overlapping red and green fluorescence as yellow regions in AML12 and HepG2 cells using con-focal microscopy (<xref rid="fig9" ref-type="fig">Figure 9A</xref>). Then using co-immunoprecipitation (Co-IP), we confirmed direct binding between TTR and SERCA2 in HEK-293T cells co-transfected with TTR-FLAG and SERCA2-MYC plasmids (<xref rid="fig9" ref-type="fig">Figure 9B</xref>, <xref ref-type="fig" rid="fig9">C</xref>). In addition, the direct interaction between TTR and SERCA2 was also observed in AML12 cells transfected with TTR-FLAG plasmid (<xref rid="fig9" ref-type="fig">Figure 9D</xref>).</p>
<fig id="fig9" position="float" orientation="portrait" fig-type="figure">
<label>Figure 9.</label>
<caption><title>Protein interaction between TTR and SERCA2 in hepatocytes.</title>
<p>(A) Immunofluorescence staining of TTR and SERCA2 in AML12 and HepG2 cells using confocal microscopy; scale bar: 10 μm. (B, C) HEK-293T cells overexpressed TTR-FLAG and SERCA2-MYC, and Co-IP was used to detect the protein interaction. (B) TTR and SERCA2 shared a common murine genetic origin. (C) TTR and SERCA2 shared a common human genetic origin. (D) AML12 cells overexpressed FLAG-TTR, and CoIP was used to detect the interaction between TTR-FLAG protein and endogenous SERCA2 protein. TTR-FLAG, TTR protein labeled with FLAG; SERCA2-MYC, SERCA2 protein labeled with MYC; Co-IP, co-immunoprecipitation.</p></caption>
<graphic xlink:href="25338095v1_fig9.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s3">
<title>Conclusions</title>
<p>Elevated hepatic TTR expression and secretion contribute to the development of NAFLD under HFD feeding. Liver-specific TTR knockdown alleviates hepatic steatosis and inflammation in NAFLD mice, potentially by improving Ca<sup>2+</sup> homeostasis through SERCA2 activation. This subsequently attenuates ER stress and reduces ER-related lipid synthesis, suggesting TTR as a potential therapeutic target for NAFLD prevention.</p>
</sec>
</sec>
<sec id="s4">
<title>Discussion</title>
<p>The pathogenesis of NAFLD is not yet fully understood, which poses a huge challenge to its treatment. Except for the THR-β agonist, Resmetirom, approved by FDA this year(<xref ref-type="bibr" rid="c14">Kang et al., 2016</xref>), there are no other FDA-approved drugs for the treatment of NAFLD. The accumulation of liver lipids, primarily TG, is the triggering factor, and inflammation is a crucial step in the progression of NAFLD. Thus, molecular factors that promote hepatic lipid deposition and inflammation may serve as potential targets for NAFLD prevention. To our knowledge, our study is the first to explore the role of TTR on NAFLD development; we found that liver-specific TTR knockdown improved calcium homeostasis via targeting SERCA2 activity, and reduced hepatic ER stress, lipid accumulation, and inflammation.</p>
<p>TTR is a homo-tetrameric protein primarily synthesized by both choroid plexuses of the brain and liver, serving as a transport carrier for thyroid hormones and retinol in the circulation. Recent studies have identified that TTR in the peripheral system is involved not only in the assessment of nutritional status but also associated with glucose metabolism and IR(<xref ref-type="bibr" rid="c17">He et al., 2021</xref>; <xref ref-type="bibr" rid="c18">Zemany et al., 2015</xref>; <xref ref-type="bibr" rid="c25">Ingenbleek and Bernstein, 2015</xref>). However, the effect of TTR on the pathogenesis and development of NAFLD remains unclear. We initially examined TTR levels in NAFLD state, and found a significant increase of <italic>Ttr</italic> mRNA expression in NASH patients compared to non-NAFLD controls. Then we observed that TTR overexpression exacerbated hepatic lipid deposition in HFD-fed mice and FFA-induced steatotic hepatocytes. In contrast, liver-specific TTR knockdown relieved lipid accumulation and inflammation in the livers of various NAFLD mouse models, indicating a role of TTR in the development of NAFLD.</p>
<p>Our prior studies have found that administration of purified TTR via the lateral ventricle inhibits appetite, contributing to body weight loss(<xref ref-type="bibr" rid="c26">Zheng et al., 2016</xref>); while in the periphery, high expression of TTR induces IR in ND mice(<xref ref-type="bibr" rid="c17">He et al., 2021</xref>). In addition, liver-specific TTR knockdown using a liver-targeting AAV vector, significantly improved IR in ob/ob mice but had no effect on body weight.</p>
<p>This suggests that TTR has distinct roles in both the central and peripheral systems(<xref ref-type="bibr" rid="c17">He et al., 2021</xref>). This may also explain why the global absence of TTR in mice does not improve metabolic phenotypes(<xref ref-type="bibr" rid="c27">Marques et al., 2007</xref>; <xref ref-type="bibr" rid="c28">Rendenbach et al., 2013</xref>). In our study, both GTT and ITT results showed that liver-specific TTR knockdown improved glucose tolerance and insulin sensitivity in NAFLD mice induced by HFD and GAN diet, independent of body weight changes, which supports a role of peripheral TTR in energy metabolism.</p>
<p>Consistently <italic>in vivo</italic> and <italic>in vitro</italic>, we observed that both HFD feeding and FFA treatment upregulated hepatic TTR expression. <italic>This TTR induction may exacerbate IR, thereby accelerating hepatic lipid accumulation and serving as the initial hit in NAFLD development.</italic> Through transcriptomic and lipidomic analyses and validation of key genes, we did find that TTR knockdown primarily inhibited lipid synthesis at the ER level, particularly the fatty acid elongation required for glycerolipid formation, whereas it had no effect on DNL and fatty acid oxidation. This is consistent with the spatial localization of exogenous TTR mainly in the ER after reuptake.</p>
<p>TTR synthesized by the liver may regulate hepatocyte metabolism through its intracellular actions and via a reuptake mechanism (i.e., autocrine action). The uptake of TTR occurs in several cell types(<xref ref-type="bibr" rid="c19">Dekki et al., 2012</xref>; <xref ref-type="bibr" rid="c29"><italic>Divino and Schussler</italic>, 1990</xref>; <xref ref-type="bibr" rid="c30"><italic>Divino and Schussler</italic>, 1990</xref>). In this study, we validated TTR internalization in hepatocytes using TTR-fluorescent protein probes. However, the cell surface receptor mediating TTR uptake in hepatocytes requires further investigation.</p>
<p>ER stress is considered to be the second hit that drives the progression of NAFLD, following the initial lipid accumulation induced by IR(<xref ref-type="bibr" rid="c23">Flessa et al., 2022</xref>; <xref ref-type="bibr" rid="c24">Lebeaupin et al., 2018</xref>). Consistent with other studies, we confirmed increased ER stress in the livers of different NAFLD mouse models.</p>
<p>Sustained and excessive ER stress can, in turn, further amplify lipid accumulation, induce oxidative stress and inflammation(<xref ref-type="bibr" rid="c31">Piccolis et al., 2019</xref>). Calcium homeostasis disruption is a primary trigger of ER stress(<xref ref-type="bibr" rid="c10">Krebs et al., 2015</xref>). In NAFLD, the accumulation of lipids in hepatocytes inhibits Store-Operated Calcium Entry (SOCE) and the ER calcium pump SERCA2, while activating calcium efflux from the ER and its transfer to the mitochondria. This contributes to the impairment of the function of calcium-dependent molecular chaperones, and subsequently activating ER stress and mitochondrial dysfunction, accelerating the progression from steatosis to steatohepatitis(<xref ref-type="bibr" rid="c32">Chen et al., 2021</xref>; <xref ref-type="bibr" rid="c33">Jacquemyn et al., 2017</xref>). Multiple studies have shown impaired activity and reduced expression of liver SERCA2 in animal models of NAFLD(<xref ref-type="bibr" rid="c7">Park et al., 2010</xref>; <xref ref-type="bibr" rid="c14">Kang et al., 2016</xref>). We consistently found that SERCA2 protein levels were suppressed in NAFLD mice induced by HFD or GAN diet, as well as in steatotic AML12 cells. An increasing number of studies have confirmed that some small molecule compounds, including CDN1163(<xref ref-type="bibr" rid="c14">Kang et al., 2016</xref>), Maresin 1(<xref ref-type="bibr" rid="c11">Jung et al., 2018</xref>), and Matrine(<xref ref-type="bibr" rid="c12">Gao et al., 2018</xref>), targeting SERCA2 activity can delay the development of NAFLD.</p>
<p>We then found that TTR’s regulation of calcium homeostasis (increasing cytoplasmic calcium levels and reducing ER calcium stores) is very similar to the effect of the SERCA inhibitor, Tg. Further in <italic>vitro</italic> studies, we confirmed a direct interaction between TTR and SERCA2, and an inhibitory effect of TTR on SERCA2 activity. Thus, we propose that in the context of NAFLD, TTR may induce calcium homeostasis abnormalities by inhibiting SERCA2 activity, thereby promoting ER stress and lipid synthesis. With growing recognition of the link between calcium homeostasis and NAFLD pathogenesis, SERCA2 activity modulators have emerged as promising therapeutic targets for NAFLD drug development. We confirmed in this study that TTR regulates SERCA2 activity, but the specific molecular mechanisms by which TTR directly inhibits SERCA2 activity warrant further research.</p>
<p>In summary, we establish that TTR knockdown alleviates NAFLD by restoring hepatocyte calcium homeostasis via SERCA2 upregulation, thereby attenuating ER stress and suppressing ER-dependent lipid synthesis in the liver. These findings further support the crucial role of calcium signaling in NAFLD and offer new insights for the development of novel calcium channel-targeted therapeutic approaches for NAFLD, e.g., targeting TTR.</p>
</sec>
<sec id="s5">
<title>Materials and methods</title>
<sec id="s5a">
<title>Sex as a biological variable</title>
<p>Our study examined male mice because male animals exhibited less variability in phenotype. It is unknown whether the findings are relevant for female mice. Therefore, we clearly stated which sexes were analyzed in the respective experiments.</p>
</sec>
<sec id="s5b">
<title>Liver specimens from patients with NAFLD</title>
<p>We collected liver sample sections from Sir Run Run Shaw Hospital, Zhejiang University. Liver samples of 5 male patients diagnosed with NASH through liver biopsy in the Infectious Disease Department were selected. Another 5 male patients who underwent cholecystectomy in the General Surgery Department and were excluded from fatty liver by ultrasound were selected as non-NAFLD controls. The liver tissue sections were analyzed independently by senior pathologists according to the SAF scoring system (“S” standing for steatosis was scored from 0 to 3, “A” standing for ballooning degeneration and lobular inflammation was scored from 0 to 4, “F” standing for fibrosis was scored from 0 to 4). The general clinical information of 10 selected patients was collected (<xref ref-type="supplementary-material" rid="supp2">Supplementary Table 1</xref>).</p>
</sec>
<sec id="s5c">
<title>Animals</title>
<p>Male C57BL/6 mice (aged 5-8 weeks) were obtained from Shanghai SLAC Laboratory Animal Co., Ltd., housed in a temperature-controlled environment with 12-hour light/12-hour dark cycle and received food and water ad libitum. Mice were fed on a ND (MD17131, Medicience), a HFD (M101160, Moldiets) or a GAN diet (D09100310, Research Diet), respectively. Body weight was measured weekly. After treatments, the mice were sacrificed, and the plasma and liver tissues were collected for analysis.</p>
<p>Cohort 1: Male C57BL/6J mice were randomly divided into four groups (n = 4 each): ND-Control group, ND-TTR overexpression group (ND-TTR-OE), HFD-Control group, and HFD-TTR-OE group. The mice were fed with ND or HFD for 19 weeks. On weeks 9 and 11, each mouse received a tail vein injection of adenovirus (1 × 10<sup>9</sup> plaque-forming units/mouse; GeneChem), with the control groups receiving control adenovirus (Ad-Control) and the TTR-OE groups receiving Ad-<italic>Ttr</italic>.</p>
<p>Cohort 2: Male C57BL/6J mice were randomly divided into four groups: ND-Control group (n = 8), ND-TTR knockdown group (ND-TTR-KD) (n = 8), HFD-Control group (n = 8), and HFD-TTR-KD group (n = 7). The mice were fed with ND or HFD for 19 weeks. On weeks 9 and 11, each mouse received a tail vein injection of recombinant adeno-associated virus bearing TBG promoter (1 × 10<sup>11</sup> plaque-forming units/mouse; GeneChem), with the control groups receiving control adeno-associated virus (AAV-TBG-Control) and the TTR-KD groups receiving AAV-TBG-sh<italic>Ttr</italic>.</p>
<p>Cohort 3: Male C57BL/6J mice were randomly divided into four groups (ND group n = 5, GAN group n = 6): ND-Control group, ND-TTR-KD group, GAN-Control group, and GAN-TTR-KD group. The mice were fed with ND or GAN diets for 17 weeks. On weeks 1 and 9, each mouse received a tail vein injection of AAV bearing TBG promoter, with the control groups receiving AAV-TBG-Control and the TTR-KD groups receiving AAV-TBG-sh<italic>Ttr</italic>.</p>
</sec>
<sec id="s5d">
<title>Cell culture and treatment</title>
<p>AML12 cells were purchased from the American Type Culture Collection (ATCC) and grown in Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12</p>
<p>(DMEM/F12) supplemented with 10% fetal bovine serum, 0.1 μM dexamethasone (D4902; Sigma-Aldrich), insulin-transferrin-selenium (I3146; Sigma-Aldrich) and 1% penicillin-streptomycin. HepG2 and HEK293T cells were purchased from ATCC and cultured in DMEM with 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C with 5% CO2.</p>
<p>To induce steatosis, the cells were treated with 0.75 mM FFA (palmitic acid: oleic acid, 1:2; Sigma-Aldrich) for 12 hours at 37°C. For TTR overexpression, AML12 cells were infected with 1.25×10<sup>7</sup> plaque-forming units/mL (PFU/mL) of Ad-Control or 5×10<sup>7</sup> PFU/mL Ad-<italic>Ttr</italic> for 48 hours. For TTR knockdown, AML12 cells were treated with small interfering (si)-<italic>Ttr</italic>1 (5’-GUCCU CUGAU GGUCA AAGUT T-3’), si-<italic>Ttr</italic>2 (5’-CCACA GAUGA GAAGU UUGUT T-3’) and si-NC (5’-UUCUC CGAAC GUGUC ACGUT T-3’) for 48 hours, which were synthesized by GenePharm. AML12 cells were transfected using Rfect siRNA transfection reagent (Cat#:11013, Baidai Biotechnology, China) according to the manufacturer’s protocol.</p>
<p>For achieving TTR-KD stable cell lines, shRNA lentiviral particle was synthesized and transfected.</p>
<p>First, lentiviral constructs for shRNA targeting TTR (sh<italic>Ttr</italic>) and shRNA control were purchased from Tsingke Biotechnology. The lentiviral sh<italic>Ttr</italic> constructs were designed with the following target sequences: 5’-AACAGTGTTCTTGCTCTATAA-3’ and 5’-CCACAGATGAGGAAGTTTGT-3’. Then, lentiviruses were produced by transfection of HEK293T cells with lentiviral constructs and pMD2.G and psPAX2 packaging constructs (Addgene). PolyJet reagents (Signagen) were used for transfection and the supernatants containing the lentiviruses were centrifuged and filtered, and then stored at -80 °C. We incubated AML12 cells with thawed lentivirus-sh<italic>Ttr</italic> or control lentivirus, together with polybrene (GeneChem) for 48 hours. For the selection of cells stably transfected with shRNA, the medium was replaced with a 10% serum medium containing 3 μg/mL puromycin (Solarbio, China) and incubated for 48 to 72 hours. Cells were replenished with medium every 3 to 4 days until several puromycin-resistant colonies were identified. Efficacy and successful shRNA transduction were verified by qRT-PCR.</p>
</sec>
<sec id="s5e">
<title>Localization of Alexa Fluor 488 labeling TTR in AML12 cells</title>
<p>Alexa Fluor 488 labeling TTR probes were synthesized as described previously(<xref ref-type="bibr" rid="c17">He et al., 2021</xref>). The mCherry-ER-3 plasmid (Addgene) was a gift from Prof. Yingke Xu (Zhejiang University). AML12 cells transfected with the mCherry-ER-3 plasmid for 48 hours were then subjected to serum starvation for 6 hours, followed by the addition of 50 μg/mL Alexa Fluor 488 labeling TTR probes and incubated at 37°C in the dark for 30 minutes. The cells were then washed with PBS to completely remove the free probes, and live cell imaging was immediately performed by confocal microscope. Alexa Fluor 488 labeling TTR was observed at an excitation wavelength of 488 nm, while the ER fluorescing red was visible under an excitation wavelength of 594 nm.</p>
</sec>
<sec id="s5f">
<title>Confocal microscopy for Ca<sup>2+</sup> imaging</title>
<p>For measuring the cytosolic Ca<sup>2+</sup> concentration in AML12 cells, cells were incubated with 2 μM Fluo-8 AM (142773, Abcam) in Hank’s Balanced Salt Solution (HBSS) without Ca<sup>2+</sup> and Mg<sup>2+</sup> for 30 min at 37°C in the dark. For measuring the Ca<sup>2+</sup> in the ER, cells were transfected with pcDNA-D1ER plasmid (36325, Addgene) for 48 hours, which was expressed to be D1ER calcium indicator equipped with an ER-targeting sequence and fluorescent proteins. For measuring the cytosolic Ca<sup>2+</sup> levels in stable cell lines with TTR knockdown, cells were incubated with 2 μM Cal-590 AM (20510, AAT Bioquest) in calcium-free HBSS for 90 min at 37°C in the dark. 5 μM thapsigargin (Sigma) was used to stimulate Ca<sup>2+</sup> release. Once added 10 μg/mL TTR or PBS or 5 μM Tg, cells were imaged every 10 to 20 seconds for 6-10 min using confocal microscopy at an excitation wavelength of 488 nm. The calcium signal was presented as the mean of the relative change in fluorescence intensity normalized to baseline intensity (ΔF/F) in 10-20 AML12 cells.</p>
</sec>
<sec id="s5g">
<title>SERCA activity analysis</title>
<p>To facilitate the transport of calcium from the cytosol into the ER lumen, SERCA facilitates the hydrolysis of ATP into ADP and inorganic phosphate. As a result, the level of inorganic phosphate serves as an indicator of SERCA activity. SERCA activity was assessed using an ultra-micro Ca²⁺-ATPase assay kit (GMS50241, GENMED). After trypsinization and centrifugation, AML12 cells were suspended in normal saline and disrupted via sonication. The protein concentration was quantified using the BCA method.</p>
</sec>
<sec id="s5h">
<title>Immunofluorescence staining</title>
<p>After 20 minutes of immersion in PBS containing 0.2% Triton X-100, the cell samples were fixed with 4% paraformaldehyde for 20 minutes, then blocked with 5% BSA for 1 hour and incubated with the primary antibody at 4°C overnight before being incubated with fluorescent-dye–conjugated secondary antibodies (Alexa Fluor 488/594, Invitrogen; 1:500). Primary antibodies used: anti-mouse-TTR (204997, Abcam; 1:100), anti-rabbit-SERCA2 (3625, Abcam; 1µg/mL), anti-rabbit-Calnexin (2670, CST; 1:100). Cell nuclei were stained with DAPI. Images were acquired by a confocal microscope.</p>
</sec>
<sec id="s5i">
<title>Co-immunoprecipitation</title>
<p>CMV-FLAG-TTR (mouse) plasmid, pcDNA3.1-FLAG-TTR (human) plasmid, pCMV-MYC-SERCA2 (mouse) plasmid, and CMV-MYC-SECRA2 (human) plasmid were purchased from GeneChem. For TTR-FLAG and SERCA2-MYC co-immunoprecipitation, HEK293T cells were transfected with mouse or human TTR-FLAG and SERCA2-MYC plasmids for 48 hours. For TTR-FLAG and SERCA2 co-immunoprecipitation, TTR-FLAG were overexpressed in AML12 cells. The cell lysates were centrifuged at 12,000 g for 15 min at 4°C. The supernatants were further incubated with primary antibodies against FLAG or MYC or IgG at 4°C overnight, then precipitated with Protein A/G beads (sc-2003, Santa Cruz) at 4°C for 4 hours. The beads were washed five then boiled in SDS buffer. SERCA2-MYC, TTR-FLAG and SERCA2 protein levels were determined via western blot.</p>
<p>Please refer to the <xref ref-type="supplementary-material" rid="supp1">Supplemental Methods</xref> for detailed materials and methods.</p>
</sec>
<sec id="s5j">
<title>Statistics</title>
<p>GraphPad Prism 9 and image J were used to analyze the values in this study. All data are presented as mean ± SEM, unless otherwise indicated and analyzed by unpaired 2-tailed t test or 1-way ANOVA if more than 2 groups were compared. Statistical significance was set at <italic>P</italic> &lt; 0.05.</p>
</sec>
<sec id="s5k">
<title>Study approval</title>
<p>All protocols and animal studies were performed in accordance with the Guide for the Care and Use of Laboratory Animals by the US NIH (NIH Publication No. 85-23; National Academies Press, 2011) and approved by the Animal Ethics Committee of Zhejiang Chinese Medical University (Approval No. 20190429-04). The human study conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the Ethics Committee of Sir Run Run Shaw Hospital. All human samples were acquired ethically with patient/guardian consent following institutional guidelines.</p>
</sec>
</sec>
</body>
<back>
<sec id="das" sec-type="data-availability">
<title>Data availability</title>
<p>Values for all data points in graphs are reported in the Supporting Data Values file. For more details on the material and methods used, please contact the corresponding author.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>We want to thank all participants for taking part in our study and consenting to donate extra Liver samples for research use. We thank Prof. Yingke Xu (Zhejiang University) for kindly providing the valuable plasmid (mCherry-ER-3) and for excellent technical assistance. This work was supported by the National Natural Science Foundation of China [81870583, 2018] and Zhejiang Provincial Natural Science Foundation of China [ZCLQN25H0701, 2025].</p>
</ack>
<sec id="additional-files" sec-type="supplementary-material">
<title>Additional files</title>
<supplementary-material id="supp1">
<label>Supplementary file 1.</label>
<media mimetype="application" mime-subtype="pdf" xlink:href="supp1.pdf"/>
</supplementary-material>
<supplementary-material id="supp2">
<label>Supplementary file 2.</label>
<media mimetype="application" mime-subtype="vnd.ms-excel" xlink:href="supp2.xlsx"/>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Quek</surname> <given-names>J</given-names></string-name>, <string-name><surname>Chan</surname> <given-names>KE</given-names></string-name>, <string-name><surname>Wong</surname> <given-names>ZY</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis</article-title>. <source>Lancet Gastroenterol Hepatol</source>. <year>2023</year>;<volume>8</volume>(<issue>1</issue>):<fpage>20</fpage>–<lpage>30</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s2468-1253(22)00317-x</pub-id></mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Henry</surname> <given-names>L</given-names></string-name>, <string-name><surname>Paik</surname> <given-names>J</given-names></string-name>, <string-name><surname>Younossi</surname> <given-names>ZM</given-names></string-name></person-group>. <article-title>Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2022</year>;<volume>56</volume>(<issue>6</issue>):<fpage>942</fpage>–<lpage>956</lpage>. doi:<pub-id pub-id-type="doi">10.1111/apt.17158</pub-id></mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Paik</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Golabi</surname> <given-names>P</given-names></string-name>, <string-name><surname>Younossi</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Mishra</surname> <given-names>A</given-names></string-name>, <string-name><surname>Younossi</surname> <given-names>ZM</given-names></string-name></person-group>. <article-title>Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD</article-title>. <source>Hepatology</source>. <year>2020</year>;<volume>72</volume>(<issue>5</issue>):<fpage>1605</fpage>–<lpage>1616</lpage>. doi:<pub-id pub-id-type="doi">10.1002/hep.31173</pub-id></mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Buzzetti</surname> <given-names>E</given-names></string-name>, <string-name><surname>Pinzani</surname> <given-names>M</given-names></string-name>, <string-name><surname>Tsochatzis</surname> <given-names>EA</given-names></string-name></person-group>. <article-title>The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)</article-title>. <source>Metabolism</source>. <year>2016</year>;<volume>65</volume>(<issue>8</issue>):<fpage>1038</fpage>–<lpage>48</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.metabol.2015.12.012</pub-id></mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Loomba</surname> <given-names>R</given-names></string-name>, <string-name><surname>Friedman</surname> <given-names>SL</given-names></string-name>, <string-name><surname>Shulman</surname> <given-names>GI</given-names></string-name></person-group>. <article-title>Mechanisms and disease consequences of nonalcoholic fatty liver disease</article-title>. <source>Cell</source> <year>2021</year>;<volume>184</volume>(<issue>10</issue>):<fpage>2537</fpage>–<lpage>2564</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2021.04.015</pub-id></mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rutkowski</surname> <given-names>DT</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Back</surname> <given-names>S-H</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators</article-title>. <source>Dev Cell</source>. <year>2008</year>;<volume>15</volume>(<issue>6</issue>):<fpage>829</fpage>–<lpage>840</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.devcel.2008.10.015</pub-id></mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname> <given-names>H-W</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>JH</given-names></string-name></person-group>. <article-title>Calcium channel blockers as potential therapeutics for obesity-associated autophagy defects and fatty liver pathologies</article-title>. <source>Autophagy</source>. <year>2014</year>;<volume>10</volume>(<issue>12</issue>):<fpage>2385</fpage>–<lpage>2386</lpage>. doi:<pub-id pub-id-type="doi">10.4161/15548627.2014.984268</pub-id></mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Periasamy</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kalyanasundaram</surname> <given-names>A</given-names></string-name></person-group>. <article-title>SERCA pump isoforms: their role in calcium transport and disease</article-title>. <source>Muscle &amp; Nerve</source>. <year>2007</year>;<volume>35</volume>(<issue>4</issue>):<fpage>430</fpage>–<lpage>442</lpage>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vangheluwe</surname> <given-names>P</given-names></string-name>, <string-name><surname>Raeymaekers</surname> <given-names>L</given-names></string-name>, <string-name><surname>Dode</surname> <given-names>L</given-names></string-name>, <string-name><surname>Wuytack</surname> <given-names>F</given-names></string-name></person-group>. <article-title>Modulating sarco(endo)plasmic reticulum Ca2+ ATPase 2 (SERCA2) activity: cell biological implications</article-title>. <source>Cell Calcium</source> <year>2005</year>;<volume>38</volume>(<issue>3-4</issue>):<fpage>291</fpage>–<lpage>302</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ceca.2005.06.033</pub-id></mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Krebs</surname> <given-names>J</given-names></string-name>, <string-name><surname>Agellon</surname> <given-names>LB</given-names></string-name>, <string-name><surname>Michalak</surname> <given-names>M</given-names></string-name></person-group>. <article-title>Ca(2+) homeostasis and endoplasmic reticulum (ER) stress: An integrated view of calcium signaling</article-title>. <source>Biochem Biophys Res Commun</source> <year>2015</year>;<volume>460</volume>(<issue>1</issue>):<fpage>114</fpage>–<lpage>21</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbrc.2015.02.004</pub-id></mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jung</surname> <given-names>TW</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>HC</given-names></string-name>, <string-name><surname>Abd El-Aty</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Jeong</surname> <given-names>JH</given-names></string-name></person-group>. <article-title>Maresin 1 attenuates NAFLD by suppression of endoplasmic reticulum stress via AMPK-SERCA2b pathway</article-title>. <source>J Biol Chem</source> <year>2018</year>;<volume>293</volume>(<issue>11</issue>):<fpage>3981</fpage>–<lpage>3988</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.RA117.000885</pub-id></mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gao</surname> <given-names>X</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>S</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>S</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>A</given-names></string-name>, <string-name><surname>Shi</surname> <given-names>L</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Y</given-names></string-name></person-group>. <article-title>Matrine attenuates endoplasmic reticulum stress and mitochondrion dysfunction in nonalcoholic fatty liver disease by regulating SERCA pathway</article-title>. <source>J Transl Med</source> <year>2018</year>;<volume>16</volume>(<issue>1</issue>):<fpage>319</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12967-018-1685-2</pub-id></mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname> <given-names>SW</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ozcan</surname> <given-names>U</given-names></string-name></person-group>. <article-title>Sarco(endo)plasmic reticulum Ca2+-ATPase 2b is a major regulator of endoplasmic reticulum stress and glucose homeostasis in obesity</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2010</year>;<volume>107</volume>(<issue>45</issue>):<fpage>19320</fpage>–<lpage>5</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1012044107</pub-id></mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kang</surname> <given-names>S</given-names></string-name>, <string-name><surname>Dahl</surname> <given-names>R</given-names></string-name>, <string-name><surname>Hsieh</surname> <given-names>W</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Small Molecular Allosteric Activator of the Sarco/Endoplasmic Reticulum Ca2+-ATPase (SERCA) Attenuates Diabetes and Metabolic Disorders</article-title>. <source>J Biol Chem</source> <year>2016</year>;<volume>291</volume>(<issue>10</issue>):<fpage>5185</fpage>–<lpage>98</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M115.705012</pub-id></mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weigert</surname> <given-names>C</given-names></string-name>, <string-name><surname>Hoene</surname> <given-names>M</given-names></string-name>, <string-name><surname>Plomgaard</surname> <given-names>P</given-names></string-name></person-group>. <article-title>Hepatokines-a novel group of exercise factors</article-title>. <source>Pflugers Arch</source>. <year>2019</year>;<volume>471</volume>(<issue>3</issue>):<fpage>383</fpage>–<lpage>396</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00424-018-2216-y</pub-id></mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Iroz</surname> <given-names>A</given-names></string-name>, <string-name><surname>Couty</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Postic</surname> <given-names>C</given-names></string-name></person-group>. <article-title>Hepatokines: unlocking the multi-organ network in metabolic diseases</article-title>. <source>Diabetologia</source>. <year>2015</year>;<volume>58</volume>(<issue>8</issue>):<fpage>1699</fpage>–<lpage>703</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00125-015-3634-4</pub-id></mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>He</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Qiu</surname> <given-names>R</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>B</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Transthyretin contributes to insulin resistance and diminishes exercise-induced insulin sensitivity in obese mice by inhibiting AMPK activity in skeletal muscle</article-title>. <source>Am J Physiol Endocrinol Metab</source> <year>2021</year>;<volume>320</volume>(<issue>4</issue>):<fpage>E808</fpage>–<lpage>E821</lpage>. doi:<pub-id pub-id-type="doi">10.1152/ajpendo.00495.2020</pub-id></mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zemany</surname> <given-names>L</given-names></string-name>, <string-name><surname>Bhanot</surname> <given-names>S</given-names></string-name>, <string-name><surname>Peroni</surname> <given-names>OD</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Transthyretin Antisense Oligonucleotides Lower Circulating RBP4 Levels and Improve Insulin Sensitivity in Obese Mice</article-title>. <source>Diabetes</source>. <year>2015</year>;<volume>64</volume>(<issue>5</issue>):<fpage>1603</fpage>–<lpage>14</lpage>. doi:<pub-id pub-id-type="doi">10.2337/db14-0970</pub-id></mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dekki</surname> <given-names>N</given-names></string-name>, <string-name><surname>Refai</surname> <given-names>E</given-names></string-name>, <string-name><surname>Holmberg</surname> <given-names>R</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Transthyretin binds to glucose-regulated proteins and is subjected to endocytosis by the pancreatic β-cell</article-title>. <source>Cell Mol Life Sci</source>. <year>2012</year>;<volume>69</volume>(<issue>10</issue>):<fpage>1733</fpage>–<lpage>43</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00018-011-0899-8</pub-id></mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname> <given-names>B</given-names></string-name>, <string-name><surname>Qiu</surname> <given-names>R</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Transthyretin knockdown recapitulates the insulin-sensitizing effects of exercise and promotes skeletal muscle adaptation to exercise endurance</article-title>. <source>J Mol Endocrinol</source> <year>2023</year>;<volume>71</volume>(<issue>1</issue>) doi:<pub-id pub-id-type="doi">10.1530/JME-22-0163</pub-id></mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kleiner</surname> <given-names>DE</given-names></string-name>, <string-name><surname>Brunt</surname> <given-names>EM</given-names></string-name>, <string-name><surname>Van Natta</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Design and validation of a histological scoring system for nonalcoholic fatty liver disease</article-title>. <source>Hepatology</source>. <year>2005</year>;<volume>41</volume>(<issue>6</issue>):<fpage>1313</fpage>–<lpage>21</lpage>. doi:<pub-id pub-id-type="doi">10.1002/hep.20701</pub-id></mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gallage</surname> <given-names>S</given-names></string-name>, <string-name><surname>Avila</surname> <given-names>JEB</given-names></string-name>, <string-name><surname>Ramadori</surname> <given-names>P</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>A researcher’s guide to preclinical mouse NASH models</article-title>. <source>Nat Metab</source>. <year>2022</year>;<volume>4</volume>(<issue>12</issue>):<fpage>1632</fpage>–<lpage>1649</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s42255-022-00700-y</pub-id></mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Flessa</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Kyrou</surname> <given-names>I</given-names></string-name>, <string-name><surname>Nasiri-Ansari</surname> <given-names>N</given-names></string-name>, <string-name><surname>Kaltsas</surname> <given-names>G</given-names></string-name>, <string-name><surname>Kassi</surname> <given-names>E</given-names></string-name>, <string-name><surname>Randeva</surname> <given-names>HS</given-names></string-name></person-group>. <article-title>Endoplasmic reticulum stress in nonalcoholic (metabolic associated) fatty liver disease (NAFLD/MAFLD)</article-title>. <source>J Cell Biochem</source>. <year>2022</year>;<volume>123</volume>(<issue>10</issue>):<fpage>1585</fpage>–<lpage>1606</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jcb.30247</pub-id></mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lebeaupin</surname> <given-names>C</given-names></string-name>, <string-name><surname>Vallee</surname> <given-names>D</given-names></string-name>, <string-name><surname>Hazari</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Hetz</surname> <given-names>C</given-names></string-name>, <string-name><surname>Chevet</surname> <given-names>E</given-names></string-name>, <string-name><surname>Bailly-Maitre</surname> <given-names>B</given-names></string-name></person-group>. <article-title>Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease</article-title>. <source>J Hepatol</source>. <year>2018</year>;<volume>69</volume>(<issue>4</issue>):<fpage>927</fpage>–<lpage>947</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jhep.2018.06.008</pub-id></mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ingenbleek</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Bernstein</surname> <given-names>LH</given-names></string-name></person-group>. <article-title>Plasma Transthyretin as a Biomarker of Lean Body Mass and Catabolic States</article-title>. <source>Adv Nutr</source>. <year>2015</year>;<volume>6</volume>(<issue>5</issue>):<fpage>572</fpage>–<lpage>80</lpage>. doi:<pub-id pub-id-type="doi">10.3945/an.115.008508</pub-id></mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zheng</surname> <given-names>F</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>YJ</given-names></string-name>, <string-name><surname>Moran</surname> <given-names>TH</given-names></string-name>, <string-name><surname>Li</surname> <given-names>H</given-names></string-name>, <string-name><surname>Bi</surname> <given-names>S</given-names></string-name></person-group>. <article-title>Central transthyretin acts to decrease food intake and body weight</article-title>. <source>Sci Rep</source>. <year>2016</year>;<volume>6</volume>:<issue>24238</issue>. doi:<pub-id pub-id-type="doi">10.1038/srep24238</pub-id></mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marques</surname> <given-names>F</given-names></string-name>, <string-name><surname>Sousa</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Oliveira</surname> <given-names>P</given-names></string-name>, <string-name><surname>Oliveira</surname> <given-names>HC</given-names></string-name>, <string-name><surname>Palha</surname> <given-names>JA</given-names></string-name></person-group>. <article-title>The absence of transthyretin does not impair regulation of lipid and glucose metabolism</article-title>. <source>Horm Metab Res</source>. <year>2007</year>;<volume>39</volume>(<issue>7</issue>):<fpage>529</fpage>–<lpage>33</lpage>. doi:<pub-id pub-id-type="doi">10.1055/s-2007-984395</pub-id></mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rendenbach</surname> <given-names>C</given-names></string-name>, <string-name><surname>Ganswindt</surname> <given-names>S</given-names></string-name>, Seitz S, <etal>et al.</etal></person-group> <article-title>Increased expression of transthyretin in leptin-deficient ob/ob mice is not causative for their major phenotypic abnormalities</article-title>. <source>Journal of Neuroendocrinology</source>. <year>2013</year>;<volume>25</volume>(<issue>1</issue>):<fpage>14</fpage>–<lpage>22</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2826.2012.02366.x</pub-id></mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Divino</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Schussler</surname> <given-names>GC</given-names></string-name></person-group>. <article-title>Receptor-mediated uptake and internalization of transthyretin</article-title>. <source>J Biol Chem</source> <day>25</day> <year>1990</year>;<volume>265</volume>(<issue>3</issue>):<fpage>1425</fpage>–<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Divino</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Schussler</surname> <given-names>GC</given-names></string-name></person-group>. <article-title>Transthyretin receptors on human astrocytoma cells</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1990</year>;<volume>71</volume>(<issue>5</issue>):<fpage>1265</fpage>–<lpage>8</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jcem-71-5-1265</pub-id></mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Piccolis</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bond</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Kampmann</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Probing the Global Cellular Responses to Lipotoxicity Caused by Saturated Fatty Acids</article-title>. <source>Mol Cell</source> <day>4</day> <year>2019</year>;<volume>74</volume>(<issue>1</issue>):<fpage>32</fpage>–<lpage>44.e8.</lpage> doi:<pub-id pub-id-type="doi">10.1016/j.molcel.2019.01.036</pub-id></mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname> <given-names>CC</given-names></string-name>, <string-name><surname>Hsu</surname> <given-names>LW</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>KD</given-names></string-name>, <string-name><surname>Chiu</surname> <given-names>KW</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>CL</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>KT</given-names></string-name></person-group>. <article-title>Emerging Roles of Calcium Signaling in the Development of Non-Alcoholic Fatty Liver Disease</article-title>. <source>Int J Mol Sci</source> <year>2021</year>;<volume>23</volume>(<issue>1</issue>). doi:<pub-id pub-id-type="doi">10.3390/ijms23010256</pub-id></mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jacquemyn</surname> <given-names>J</given-names></string-name>, <string-name><surname>Cascalho</surname> <given-names>A</given-names></string-name>, <string-name><surname>Goodchild</surname> <given-names>RE</given-names></string-name></person-group>. <article-title>The ins and outs of endoplasmic reticulum-controlled lipid biosynthesis</article-title>. <source>EMBO Reports</source>. <year>2017</year>;<volume>18</volume>(<issue>11</issue>):<fpage>1905</fpage>–<lpage>1921</lpage>. doi:<pub-id pub-id-type="doi">10.15252/embr.201643426</pub-id></mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.109425.1.sa1</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Rutkowski</surname>
<given-names>Tom</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-6586-4449</contrib-id>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/036jqmy94</institution-id><institution>University of Iowa</institution>
</institution-wrap>
<city>Iowa City</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Important</kwd>
</kwd-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Incomplete</kwd>
<kwd>Solid</kwd>
</kwd-group>
</front-stub>
<body>
<p>This potentially <bold>important</bold> study examines the consequences of manipulating the expression of thyroxine-binding and amyloidogenic hepatocyte secretory protein transthyretin (TTR). <bold>Solid</bold> in vivo evidence from two dietary models supports that TTR production exacerbates liver injury, whereas the evidence for a link between TTR production, uptake, and calcium dysregulation is <bold>incomplete</bold>. If the findings are confirmed, they would provide evidence for a novel cell biological pathway of liver injury.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.109425.1.sa0</article-id>
<title-group>
<article-title>Joint Public Review:</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary</p>
<p>Non-alcoholic fatty liver disease (NAFLD) is a widespread metabolic disease associated with obesity. Endoplasmic reticulum and calcium dysregulation are hallmarks of NAFLD. Here, the authors explore whether the secreted liver protein transthyretin (TTR), which has been previously shown to modulate calcium signaling in the context of insulin resistance, could also impact NAFLD. The study is motivated by a small cohort of NASH patients who show elevated TTR levels. The authors then overexpress TTR in two mouse obesogenic models, which leads to elevated liver lipid deposition. In contrast, liver-specific TTR knockdown improves some liver lipid levels, reduces inflammation markers, and improves glucose tolerance, overall improving the NAFLD markers. These phenotypic findings are overall convincing and largely consistent in two different diet models.</p>
<p>Because of TTR's connection to calcium regulation, the authors then assess whether the knockdown affects ER stress and impacts SERCA2 expression. However, the direct mechanistic evidence supporting the central claim that TTR physically interacts with and inhibits the SERCA2 calcium pump is preliminary and requires further validation. Whether the broader effects on lipid accumulation, inflammation markers, and glucose tolerance are mechanistically connected remains to be determined.</p>
<p>Strengths</p>
<p>The premise of the study is built on prior work from the authors identifying a link between increased transthyretin secretion and the development of insulin resistance, a related obesity condition. The in vivo studies are comprehensive, using human NASH samples, two distinct diet-induced mouse models (HFD and GAN), and in vitro hepatocyte models. The phenotypic data showing that TTR knockdown alleviates steatosis, inflammation, and insulin resistance are robust and convincing across these systems.</p>
<p>Weaknesses</p>
<p>The mechanistic studies in Figures 6-9 are incomplete. There are several issues encompassing experimental design, rigor, and interpretation that, if properly addressed, would make the study much stronger.</p>
<p>(1) Exogenous TTR that is endocytosed by cells is unlikely to ever find itself inside the lumen of the ER. Conversely, endogenous TTR that is produced in cells and that has not yet been secreted is almost certain to have an ER lumenal localization (as in Figures 7B and 9A, and where an apparent colocalization with SERCA is likely to be incidental). In a model where TTR, acting as a hepatokine, has inhibitory effects on SERCA, these would almost certainly be realized from the cytosolic side of the ER membrane-a region inaccessible to lumenal endogenous TTR. It is possible that the overexpression and knockdown of endogenous TTR have the effects seen due to its secretion and uptake (that is, cell-non-autonomous effects), but this possibility was not directly tested through Transwell or similar assays. Given the identity of TTR as a secretory pathway client protein, the only localization data for TTR that are unexpected are those suggesting an ER localization of exogenously added TTR (Figure 7A), but this localization seems to involve only a minor population of TTR, is hindered by a technical issue with cell permeabilization (see below), and lacks orthogonal approaches to convincingly demonstrate meaningful localization of exogenous TTR at the ER membrane.</p>
<p>(2) The experimental logic in Figure 8 is problematic. The authors use Thapsigargin (Tg), a potent and specific SERCA inhibitor, to probe SERCA function. However, since both Tg and TTR are proposed to inhibit SERCA2, the design lacks a critical control to demonstrate that TTR's effects are indeed mediated through SERCA2. SERCA2 activity should, in principle, be fully and irreversibly inhibited by Tg treatment, especially using such a high concentration (5 µM). If TTR's effect on calcium flux is exclusively through SERCA2, then SERCA2 impairment by TTR should have no additional effect in the presence of Tg, as Tg would already be maximally inhibiting the pump. The current data (Figures 8G-H) showing an effect of TTR-KD even with Tg present is difficult to interpret and may suggest off-target or compensatory mechanisms.</p>
<p>(3) The coIP data in Figure 9 need to be better controlled, including by overexpression of FLAG- and MYC-tagged irrelevant proteins, ideally also localized to the ER. The coIP of overexpressed TTR with endogenous SERCA in Figure 9D, in addition to requiring a more rigorous control, is itself of relatively low quality, with the appearance of a possible gel/blotting artifact.</p>
<p>(4) The ER stress markers in Figure 6 are not convincing. Molecular weight markers and positive controls (for example, livers from animals injected with tunicamycin) are missing. In addition, the species of ATF6 that is purportedly being detected (cleaved or full-length) is not indicated, and this protein is also notoriously difficult to detect with convincing specificity in mouse tissues. As well, CHOP protein is usually not detectable in control normal diet mouse livers, raising questions of whether the band identified as CHOP is, in fact, CHOP. These issues, along with the observation that ER stress-regulated RNAs are not altered (Figure S5), raise the question of whether ER stress is involved at all. Likewise, the quantification of SERCA2 levels from Figure 6 requires more rigor. For all blots, it isn't clear that analyzing only 3 or 4 of the animals provides adequate and unbiased power to detect differences; in addition, in Figure 6C, at least the SERCA2 exposure (assuming SERCA2 is being specifically detected; see above) is well beyond the linear range of quantification.</p>
<p>In addition, the following important issues were raised:</p>
<p>(5) n=4 for overexpression might not provide adequate statistical power.</p>
<p>(6) The error for human NASH samples and controls in Figure 1A is surprisingly small. Larger gene expression data sets from NASH cohorts exist and should be used to test the finding in a larger population.</p>
<p>(7) For experiments involving two independent variables (e.g., diet and TTR manipulation, as in Figures 2, 3, 4, 5), a Two-way ANOVA must be used instead of One-way ANOVA or t-tests. Also, the ND-TTR-KD group is missing - these data are an essential control to show the specificity of the knockdown and its effects in a non-diseased state.</p>
<p>(8) Figure 7A: The co-localization signal between TTR-Alexa488 and the ER marker is not strong or convincing, which could be due to the inappropriate immunofluorescence protocol used, of permeabilization prior to fixation. The standard and recommended order is fixation first (to preserve cellular architecture), followed by permeabilization.</p>
</body>
</sub-article>
</article>